Brookfield Infrastructure Partners LP vs Cassava Sciences Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $39.38 (market cap $17.46B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Brookfield Infrastructure Partners LP is far larger — about 365.7× Cassava Sciences Inc's market cap, and Brookfield Infrastructure Partners LP pays a 4.79% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| BIP | FLNA | |
|---|---|---|
Market Cap | $17.46B | $47.75M |
Sector | Industrials | Health |
52-Week High | $42.62 | $4.64 |
52-Week Low | $29.81 | $0.87 |
Enterprise Value | $76.41B | -$34.93M |
Dividend Yield | 4.79% | — |
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.04, up 0.26% on the day, with a bullish technical signal and strong analyst support. The stock shows a high P/E ratio of 61.26 but attractive EV/EBITDA of 6.91, while recent earnings misses in Q4 2025 and Q1-Q2 2026 contrast with positive cash flow trends and a 2.6% net income margin. Recent news highlights dividend strength and corporate simplification efforts.
Outlook remains positive with a consensus price target of $44.67, offering ~14% upside, supported by bullish sentiment and infrastructure demand. Risks include earnings volatility, high debt-to-asset ratio of 69.68%, and macroeconomic pressures on profitability. The dividend yield and institutional interest provide stability, but execution on guidance is critical.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Trailing returns across standard periods
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →